Pewal and others holding/following AVX, ann out and definitely worth a read...one of the opening paragraphs of relevance
Interim CEO Jonathan Coates "Smaller biotech companies usually seek co-development partners out of necessity. That’s because the cost, the risk and the expertise involved in the Phase III trials needed for drug approval are often beyond their reach.
That isn’t the case for us. The low cost and risk of the single trial needed to gain regulatory approval for ATC, together with our expertise, mean we can manage the clinical development and approval process in-house. This gives us greater flexibility in looking for partners and means partnering with a company that can market and sell ATC is a viable option.
It also gives us the opportunity to achieve a better deal, since co-development deals,where a large pharma assumes a lot of the costs and risks, always result in lower revenues for the small biotech. openbriefing.com"
